Magazine Article | March 8, 2017

The Uphill Battle Of A Biotech That Switched Its Focus

Source: Life Science Leader

By Dan Schell, Editorial Director, Life Science Leader

By Dan Schell, editorial director

When Roger Crystal, M.D., says that he understands the importance of being “flexible” in the business of biotech, he’s not spouting typical ambiguous CEO-speak. In his case, he’s referring to his company’s willingness to pivot, to “pause” a path that they had invested years of time and resources to and choose a new core objective. That’s not an easy decision to make, and its ramifications stretched the definition of “flexible” for Crystal and his team at Opiant Pharmaceuticals.